NCT00089102 2018-07-16
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
Medical University of South Carolina
Phase 2 Terminated
Clinical Trials
11 trialsNCT00496587 2017-07-19
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00401128 2017-04-20
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00004095 2017-04-18
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
Northwestern University
Phase 1 Completed
NCT00630409 2017-03-10
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
University of Pittsburgh
Phase 2 Completed
NCT00042965 2016-07-14
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00556049 2016-04-21
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT01834183 2013-06-19
Tivozanib + Gemcitabine in Metastatic RCC
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT00491075 2013-04-24
Pemetrexed Plus Gemcitabine in Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00003928 2010-06-11
Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00496301 2009-01-14
SOGUG-02-06
Spanish Oncology Genito-Urinary Group
Phase 2 Completed